Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

May 1, 2023

Study Completion Date

May 1, 2023

Conditions

Type 1 DiabetesPeripheral Neuropathy

Interventions

DRUG

Salsalate

1 gram, 3 times daily by mouth (total of 3 grams daily)

DRUG

PLACEBO

Placebo for Salsalate; 2 Tablets, 3 times daily by mouth (total of 3 grams daily)

Trial Locations (2)

Veterans Administration Ann Arbor Health Center, Ann Arbor

University of Michigan Health System, Ann Arbor

All Listed Sponsors

lead

University of Michigan

OTHER

NCT02936843 - Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy | Biotech Hunter | Biotech Hunter